mainly found in lung cancer, breast cancer, pancreatic cancer, and others. The NRG1 gene fusion leads to abnormal activation of signaling pathways through the ERBB family (especially ERBB3 and ERBB2/HER2), which promotes the growth and differentiation of cancer cells. Therefore, targeted therapies...
Clinicopathological features and optimal treatment strategies remain unclear. Methods: A global, multicenter network of thoracic oncologists (6 countries, 13 institutions) identified NRG1 fusion-positive (NRG1+) NSCLCs. Anonymized clinical/pathologic features and clinical outcomes were collected ...
[2]Duruisseaux M, Liu SV, Han JY, et al. NRG1 fusion-positive lung cancers: clinicopathologic profile and treatment outcomes from a global multicenter registry. J Clin Oncol. 2019;37. Abstract 9081. [3]Laskin J, Liu SV, Tolba K, et al. NRG1 fusion-driven tumors: biology, detection,...
2023 年 6 月 29 日,MERUS公司宣布FDA授予旗下的泽妥珠单抗(zenocutuzumab,MCLA-128)突破性疗法认定(BTD),用于既往接受过系统性治疗后进展或没有满意的替代治疗选择的晚期不可切除或转移性NRG1融合(NRG1+)胰腺癌患者。这项批准得到了正在进行的 1/2 期 eNRGy试验EAP的数据支持,该研究正在评估泽妥珠单抗单药...
[18] Jones, M. R., et al. "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer." Annals of Oncology 28.12 (2017): 3092-3097.[19] Weinstein, Edward J., Stefan Grimm, and Philip Leder. "The oncogene heregulin induces apoptosis in breast ...
R., et al. "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer." Annals of Oncology 28.12 (2017): 3092-3097.[19] Weinstein, Edward J., Stefan Grimm, and Philip Leder. "The oncogene heregulin induces apoptosis in breast epithelial cells and ...
Afatinib is a pan-ErbB family inhibitor that may be an effective treatment for NRG1 fusion-driven tumors. Patients and methods: This report summarizes pertinent details, including best tumor response to treatment, for six patients with metastatic NRG1 fusion-positive tumors treated with afatinib. ...
“This medicine fills an important need among patients withNRG1fusionpancreatic adenocarcinoma and lung cancer who have not previously had targeted treatment options,” said Alison Schram M.D., an attending medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Cente...
Invasive mucinous lung adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma with no effective treatment option in advanced disease.KRASmutations occur in 28–87% of the cases.NRG1fusions were recently discovered inKRAS‐negativeIMAcases and otherwise negative for known driver oncogenes and ...
Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers : Episode 9 Commentary Video June 14, 2024 Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer Author(s): E. Gabriela Chiorean, MD, FASCOE. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent ...